Vascular Biogenics Ltd. - Ordinary Shares (VBLT): Price and Financial Metrics

Vascular Biogenics Ltd. - Ordinary Shares (VBLT)

Today's Latest Price: $1.14 USD

0.00 (0.00%)

Updated Sep 25 4:00pm

Add VBLT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

VBLT Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for VBLT is 0.02 -- better than just 9.59% of US stocks.
  • With a price/sales ratio of 56.11, Vascular Biogenics Ltd has a higher such ratio than 96.1% of stocks in our set.
  • The volatility of Vascular Biogenics Ltd's share price is greater than that of only 4.99% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Vascular Biogenics Ltd are XENE, NTLA, MORF, KALV, and MGNX.
  • Visit VBLT's SEC page to see the company's official filings. To visit the company's web site, go to
VBLT Daily Price Range
VBLT 52-Week Price Range

VBLT Stock Price Chart Technical Analysis Charts

VBLT Price/Volume Stats

Current price $1.14 52-week high $1.64
Prev. close $1.14 52-week low $0.90
Day low $1.13 Volume 46,299
Day high $1.16 Avg. volume 446,770
50-day MA $1.27 Dividend yield N/A
200-day MA $1.29 Market Cap 47.80M

Vascular Biogenics Ltd. - Ordinary Shares (VBLT) Company Bio

Vascular Biogenics Limited is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases. The company was founded in 2000 and is based in Or Yehuda, Israel.

VBLT Latest News Stream

Event/Time News Detail
Loading, please wait...

VBLT Latest Social Stream

Loading social stream, please wait...

View Full VBLT Social Stream

Latest VBLT News From Around the Web

Below are the latest news stories about Vascular Biogenics Ltd that investors may wish to consider to help them evaluate VBLT as an investment opportunity.

VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

TEL AVIV, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held virtually September 21-23, 2020. Presentation Details: Date:Wednesday, September 23 Time:10AM Eastern Time. Webcast:Webcast Link An archive recording will be available for listening after the event, on the Investor Relations page of VBL’s corporate website, under “Events & Presentations.”About VBL Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage bioph...

Yahoo | September 21, 2020

VBL Therapeutics to Provide an Update on the OVAL Study Today at the H. C. Wainwright 22nd Annual Global Investment Conference

TEL AVIV, Israel, Sept. 15, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will present today a corporate overview, including an update on the OVAL pivotal study, at the H. C. Wainwright 22nd Annual Global Investment Conference being held virtually on September 14-16, 2020.   "Our OVAL trial of VB-111 in ovarian cancer continues to progress well, with over a third of the study participants already enrolled," said Dror Harats, MD, Chief Executive Officer of VBL Therapeutics. "We are pleased that the high response rate seen in our interim analysis in March, continues to be high in the total patient population to date. With blinded data becoming more mature, we currently see a good correlation between the CA-125 and RECIST responses, as well as with preliminary PF...

Yahoo | September 15, 2020

VBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple Sclerosis at the MS Virtual 2020 Meeting

TEL AVIV, Israel, Sept. 11, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today presents for the first time new data demonstrating ex-vivo activity of its proprietary investigational anti-MOSPD2 mAbs in patients with relapsing-remitting and progressive multiple sclerosis (MS). VBL's study is being presented at the MS Virtual 2020, the virtual 8th Joint ACTRIMS-ECTRIMS Meeting. Data show that VBL's anti-MOSPD2 mAbs significantly inhibited migration of monocytes isolated from all MS patients included in the study (n=33) by up to 97%, regardless of disease severity, gender or active treatment. Notably, the activity was seen not only in the monocytes from relapsing-remitting, but also those from primary progressive and secondary progressive patients with high Expanded D...

Yahoo | September 11, 2020

VBL Therapeutics Announces Enrollment of the First Patients in the Phase 2 Clinical Trial of VB-111 in Metastatic Colorectal Cancer

* Study to investigate for the first time a combination of VB-111 with the checkpoint inhibitor, nivolumab.TEL AVIV, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that the first two patients have been enrolled in the Phase 2 clinical trial of VB-111 in combination with nivolumab (Opdivo®), an immune checkpoint inhibitor, for the treatment of metastatic colorectal cancer. The study is being conducted under a Cooperative Research and Development Agreement (CRADA) between the National Cancer Institute (NCI) and VBL.“Colon cancer is one of the most common cancers worldwide, but immune-based approaches in gastrointestinal cancers have unfortunately been largely unsuccessful,” said Tim F. Greten, M.D., Deputy Branch Chief & Senior Investigator of t...

Yahoo | September 10, 2020

VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601

* Alignment with FDA on the path forward for the development of VB-601 TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today the successful completion of a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for VB-601. VB-601 is the Company’s lead anti-MOSPD2 antibody for immune-inflammatory indications, for which a briefing package for the pre-IND meeting was submitted in June. Based on the FDA's feedback, VBL plans to advance its IND-enabling activities for VB-601 as planned.“We are very pleased with the outcome of the pre-IND meeting with the FDA,” said Dror Harats, M.D., CEO of VBL Therapeutics. “VB-601 is a first-in-class product candidate that has a completely nove...

Yahoo | September 8, 2020

Read More 'VBLT' Stories Here

VBLT Price Returns

1-mo -10.24%
3-mo -10.94%
6-mo -15.56%
1-year -8.92%
3-year -80.17%
5-year -84.92%
YTD -5.00%
2019 23.71%
2018 -86.34%
2017 46.39%
2016 -7.79%
2015 -11.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7903 seconds.